PRESS RELEASE published on 12/09/2025 at 07:30, 8 months 3 days ago OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation OSE Immunotherapeutics unveils 2026–2028 strategic plan focusing on Tedopi's phase 3, rare indications for Lusvertikimab, subcutaneous formulation in UC, and maintaining scientific leadership Strategic Plan Scientific Leadership OSE Immunotherapeutics Tedopi Phase 3 Lusvertikimab Indications
PRESS RELEASE published on 10/16/2025 at 19:58, 9 months 26 days ago RAPPORT FINANCIER SEMESTRIEL 2025
BRIEF published on 10/15/2025 at 19:05, 9 months 27 days ago OSE Immunotherapeutics publie ses résultats financiers du premier semestre 2025 Baisse Des Revenus OSE Immunotherapeutics Dépenses De R&D Piste De Trésorerie Résultats Financiers 2025
BRIEF published on 10/15/2025 at 19:05, 9 months 27 days ago OSE Immunotherapeutics Reports 2025 First Half Financial Results Revenue Decline OSE Immunotherapeutics Cash Runway R&D Expenses 2025 Financial Results
PRESS RELEASE published on 10/15/2025 at 19:00, 9 months 27 days ago OSE Immunotherapeutics Reports First Half 2025 Financial Results OSE Immunotherapeutics reports first half 2025 financial results with operating loss of 15.8 million euros and net loss of 15.1 million euros. Research and development expenses increased 6.7% Financial Results Net Loss Operating Loss OSE Immunotherapeutics Research And Development Expenses
PRESS RELEASE published on 10/15/2025 at 19:00, 9 months 27 days ago OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025 OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025, montrant une perte nette de 15,1 millions d'euros. Les activités sont estimées financées jusqu'au 4ème trimestre 2026 Résultats Financiers Biotechnologie Perte Nette OSE Immunotherapeutics Horizon De Trésorerie
BRIEF published on 10/09/2025 at 16:02, 10 months 2 days ago OSE Immunotherapeutics : Fin d'une action de concert entre actionnaires Actionnaires Franchissement De Seuil Capital Et Droits De Vote OSE Immunotherapeutics Pacte Résilié
BRIEF published on 10/09/2025 at 16:02, 10 months 2 days ago OSE Immunotherapeutics: End of a concerted action between shareholders Shareholders Threshold Crossing OSE Immunotherapeutics Capital And Voting Rights Terminated Agreement
PRESS RELEASE published on 10/09/2025 at 15:57, 10 months 2 days ago Franchissement de seuils Fin de convention et action de concert chez OSE Immunotherapeutics suite à franchissement de seuils de M. Emile Loria, Mme Dominique Costantini, M. Alexis Peyroles, MS Medical Synergy SA et Aperana Consulting SARL OSE Immunotherapeutics Franchissement Seuils Fin Convention Action Concert Emile Loria
BRIEF published on 09/30/2025 at 19:35, 10 months 11 days ago OSE Immunotherapeutics: Reorganization of the Board of Directors Board Of Directors Biotechnology Immunotherapy OSE Immunotherapeutics Markus Cappel
Published on 08/12/2026 at 13:00, 25 minutes ago Rocky Shore Identifies the Mosquito Target Horizon at the Gold Anchor Project
Published on 08/12/2026 at 12:30, 55 minutes ago Relevant Gold Commences 5,000-Metre Drill Program and Updates Exploration Model at the Lewiston Project in Wyoming, USA
Published on 08/12/2026 at 11:30, 1 hour 55 minutes ago American Critical Minerals Announces the Execution of the Drilling Contract with Drake Well Service and Mobilization to the Green River Project
Published on 08/12/2026 at 09:01, 4 hours 24 minutes ago Apex Drills 4.48% REO Over 8.0 m and 5.27% REO Over 10.2 m Within Multiple ~ 150 m Intervals of > 2.00 % REO at the Rift Rare Earth Project in SE Nebraska
Published on 08/12/2026 at 12:21, 1 hour 4 minutes ago EQS-Adhoc: Klöckner & Co SE: Delisting will take effect on August 12, 2026 in accordance with the resolution of the Frankfurt Stock Exchange
Published on 08/12/2026 at 11:50, 1 hour 35 minutes ago German Offtake Partner to Double Volumes to 40,000 tpa
Published on 08/12/2026 at 11:47, 1 hour 37 minutes ago SME bond market H1 2026: Issuance activity picks up, placement becomes more challenging
Published on 08/12/2026 at 11:31, 1 hour 53 minutes ago Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 08/11/2026 at 17:45, 19 hours 40 minutes ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 19 hours 45 minutes ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 1 day 19 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 1 day 19 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
